This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants are more likely (4 out of 5) to get semaglutide than the "dummy" medicine. The study medicine will be injected briefly, under skin, with a thin needle, typically in the stomach, thighs, or upper arms. After receiving first dose, the dose of semaglutide will be gradually increased until reaching the target dose. The study will last for about 1.5 years.
2 Primary · 27 Secondary · Reporting Duration: From baseline (week 0) to end of study (week 81)
500 Total Participants · 3 Treatment Groups
Primary Treatment: Semaglutide 7.2 mg · Has Placebo Group · Phase 3
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|Did not meet criteria||7.7%|
|Novo Nordisk Investigational Site - Austin||44.4%|
|Novo Nordisk Investigational Site||33.3%|